Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.
文献类型：期刊论文
| 作者 | Song, Yuqin; Gao, Quanli; Zhang, Huilai; Fan, Lei; Zhou, Jianfeng; Zou, Dehui; Li, Wei; Yang, Haiyan; Liu, Ting; Wang, Quanshun |
| 刊名 | JOURNAL OF CLINICAL ONCOLOGY
 |
| 出版日期 | 2021-05-20 |
| 卷号 | 39 |
| ISSN号 | 0732-183X |
| DOI | 10.1200/JCO.2021.39.15_suppl.e19507 |
| 资助项目 | BeiGene (Beijing) Co., Ltd |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000708120304144 |
| 出版者 | LIPPINCOTT WILLIAMS & WILKINS |
| 资助机构 | BeiGene (Beijing) Co., Ltd |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/126670]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Jilin Univ, Hosp 1, Canc Ctr, Dept Hematol, Changchun, Peoples R China 2.Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China 3.Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China 4.Tongji Med Coll, Tongji Hosp, Dept Hematol, Wuhan, Peoples R China 5.Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Collaborat Innovat Ctr Canc Personalized Med, Nanjing, Peoples R China 6.Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China 7.Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Immunotherapy, Zhengzhou, Peoples R China 8.BeiGene USA Inc, San Mateo, CA USA 9.Peking Univ Canc Hosp & Inst, Beijing Canc Hosp, Dept Lymphoma, Beijing, Peoples R China 10.BeiGene Beijing Co Ltd, Beijing, Peoples R China |
| 推荐引用方式 GB/T 7714 | Song, Yuqin,Gao, Quanli,Zhang, Huilai,et al. Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39. |
| APA | Song, Yuqin.,Gao, Quanli.,Zhang, Huilai.,Fan, Lei.,Zhou, Jianfeng.,...&Zhu, Jun.(2021).Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study..JOURNAL OF CLINICAL ONCOLOGY,39. |
| MLA | Song, Yuqin,et al."Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.".JOURNAL OF CLINICAL ONCOLOGY 39(2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。